Hikma Pharmaceuticals PLC Strategy, SWOT and Corporate Finance Report [Report Updated: 28072018] Prices from USD $175

16:34 EDT 30 Sep 2018 | BioPortfolio Reports

Hikma Pharmaceuticals PLC Strategy, SWOT and Corporate Finance Report


Summary


Hikma Pharmaceuticals PLC Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.


Key Highlights


Hikma Pharmaceuticals Hikma or 'the company' is engaged in the development, manufacturing and marketing of generic and inlicensed pharmaceutical products. The company offers diversified product portfolio and pipeline across a broad range of therapeutic categories including: antiinfectives, cardiovascular, central nervous system, diabetes, oncology, pain management and respiratory. It offers its products in various dosage forms including tablets, capsules, solutions and suspensions. The company markets its products under brands such as Amoclan, Blopress, Suprax , Omnicef, Prograf, Suprax and Cresemba. Hikma sells its products through leading wholesalers, pharmacy chains, governments and hospital purchasing organisations. The company primarily operates in the Middle East and North Africa MENA, the US and Europe. Hikma is headquartered in London, the UK.


Scope


Detailed information on Hikma Pharmaceuticals PLC required for business and competitor intelligence needs

A study of the major internal and external factors affecting Hikma Pharmaceuticals PLC in the form of a SWOT analysis

An indepth view of the business model of Hikma Pharmaceuticals PLC including a breakdown and examination of key business segments

Intelligence on Hikma Pharmaceuticals PLC's mergers and acquisitions MandA, strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

News about Hikma Pharmaceuticals PLC, such as business expansion, restructuring, and contract wins

Large number of easytograsp charts and graphs that present important data and key trends


Reasons to buy


Gain understanding of Hikma Pharmaceuticals PLC and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Hikma Pharmaceuticals PLC as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Hikma Pharmaceuticals PLC's business structure, strategy and prospects.

More From BioPortfolio on "Hikma Pharmaceuticals PLC Strategy, SWOT and Corporate Finance Report [Report Updated: 28072018] Prices from USD $175"